Table 1 Clinical characteristics of study population
From: Hyperglycemia as a risk factor for the development of retinopathy of prematurity
No ROP | Any ROP | p-value | |
|---|---|---|---|
(n = 412) | (n = 170) | ||
Birthweight gm (mean) | 1080 ± 272 | 831 ± 266 | < 0.0001 |
Gestational age, weeks (mean) | 28.1 ± 1.8 | 25.8 ± 1.9 | < 0.0001 |
One minute APGAR (mean) | 5.5 ± 2.3 | 4.4 ±2.2 | < 0.0001 |
Five minute APGAR (mean) | 7.5 ± 1.5 | 6.5 ± 1.9 | < 0.0001 |
Male gender (%) | 50.5 | 53.5 | 0.52 |
C-section (%) | 72.8 | 67.1 | 0.19 |
Antenatal steroids (%) | 90.7 | 87.3 | 0.15 |
Small for gestational age (%) | 15.6 | 13.5 | 0.53 |
Patent ductus arteriosus (%) | 35.2 | 66.5 | < 0.0001 |
Intraventricular hemorrhage (%) | 18.2 | 31.8 | < 0.0006 |
Necrotizing enterocolitis (%) | 2.9 | 4.1 | 0.62 |
Neonatal sepsis (%) | 20.6 | 42.4 | < 0.0001 |
Neonatal steroid therapy (%) | 14.6 | 50 | < 0.0001 |
Hyperglycemia days (mean) | 2.3 ± 3.2 | 7.1 ± 6.6 | < 0.0001 |
Ventilator days (mean) | 17.0 ± 20.6 | 49.6 ± 47.7 | < 0.0001 |